Abbott Laboratories $ABT Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. raised its stake in Abbott Laboratories (NYSE:ABT) by 0.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 173,154,308 shares of the healthcare product maker’s stock after acquiring an additional 353,457 shares during the quarter. Vanguard Group Inc. owned approximately 9.96% of Abbott Laboratories worth $23,192,288,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. IMG Wealth Management Inc. raised its stake in Abbott Laboratories by 759.1% in the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after purchasing an additional 167 shares during the last quarter. Cloud Capital Management LLC purchased a new stake in shares of Abbott Laboratories during the third quarter worth about $29,000. Guerra Advisors Inc acquired a new position in shares of Abbott Laboratories in the third quarter valued at approximately $31,000. Anfield Capital Management LLC lifted its stake in shares of Abbott Laboratories by 81.3% during the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after buying an additional 104 shares during the period. Finally, Delos Wealth Advisors LLC acquired a new stake in Abbott Laboratories during the second quarter worth approximately $32,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 1.0%

Shares of NYSE:ABT opened at $112.63 on Monday. The stock has a 50-day simple moving average of $119.48 and a 200-day simple moving average of $126.39. The stock has a market capitalization of $195.84 billion, a P/E ratio of 30.28, a PEG ratio of 1.79 and a beta of 0.75. Abbott Laboratories has a 1 year low of $105.27 and a 1 year high of $141.23. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The firm had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. During the same period in the previous year, the company posted $1.34 earnings per share. Abbott Laboratories’s revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, February 13th. Investors of record on Thursday, January 15th were issued a $0.63 dividend. The ex-dividend date was Thursday, January 15th. This represents a $2.52 annualized dividend and a yield of 2.2%. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s payout ratio is currently 67.74%.

Insider Buying and Selling

In related news, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The stock was bought at an average price of $108.73 per share, with a total value of $1,087,300.00. Following the completion of the transaction, the director directly owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. This represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.46% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of recent analyst reports. Royal Bank Of Canada reduced their price target on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Daiwa Securities Group decreased their price target on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a research note on Friday, January 30th. The Goldman Sachs Group dropped their price objective on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Piper Sandler decreased their target price on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research report on Friday, January 23rd. Finally, Freedom Capital raised shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 29th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average target price of $137.05.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.